MedTrace Logo

Enalapril in Collagen Type 4 Nephropathy

NCT01465126 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2011-11-04

No results posted yet for this study

Summary

Background: Collagen IV-related nephropathies can lead to End Stage Renal Disease. Experimental studies have shown renin angiotensin aldosterone system blockade can reduce proteinuria and preserve renal function. In humans there is no proven treatment. Methods: This is a retrospective study of patients with Collagen IV-related nephropathies and proteinuria treated with enalapril analyzing the evolution of proteinuria and renal function, as well as predictive variables of progression to end stage renal disease. Outcome was creatinine clearance \< 60 ml/min/1.73m2.

Conditions

  • Collagen Type-4 Nephropathies

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-10-31
Completion
2011-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01465126 on ClinicalTrials.gov